We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Malaria Rapid Diagnostic Test Evaluated At Point-Of-Care

By LabMedica International staff writers
Posted on 22 Apr 2015
For over a decade, the development of malaria rapid diagnostic tests (RDTs) has enabled reliable biological diagnostic testing in all situations where previously only clinical diagnosis was available. More...
These RDTs are generally considered as point-of-care tests.

Most of the studies assessing the performance of malaria RDTs are conducted by trained scientific teams that are not representative of the classical end-users, who are typically unskilled in traditional laboratory techniques for diagnosing malaria. Consequently, only the basic performance of malaria RDTs is evaluated and information regarding their overall performance when they are used by the traditional end-users is lacking.

Scientists at the Institut Pasteur du Cambodge (Phnom Penh, Cambodia) tested three types of sample (negative, low positive, high positive) in replicates of four, corresponding to a panel of 20 aliquots, as followed: one negative sample, one low positive sample at 200 parasites of Plasmodium falciparum/μL, one low positive sample at 200 parasites of P. vivax/μL, one high positive sample at 2,000 parasites of P. falciparum/μL and one high positive sample at 2,000 parasites of P. vivax/μL. Twenty end-users with four different profiles in seven communes in Kampot Province (Cambodia) were selected.

The ready-to-use cassette device the VIKIA Malaria Ag Pf/Pan (IMACCESS/bioMérieux; Lyon, France) was the RDT used. This test is based on immunochromatographic technology for detecting P. falciparum and other species of Plasmodium (P. vivax, P. malariae, and P. ovale). The team performed a quality control assessment of the set of the 20 aliquots at three different times (at the start, middle and end of the study), to confirm the good quality of the aliquots distributed to the users and to verify that no degradation occurred during transport or storage that could affect the expected results.

All results obtained by the end-users were consistent with the expected results, except for the low positive (200 parasites/μL) P. vivax aliquot (35% of concordant results). No significant difference was observed between the different end-users. End-user interviews evaluating ease-of-use and ease-of-reading of the VIKIA Malaria Ag Pf/Pan kit recorded 159 positive answers and only one negative answer. Out of 20 end-users, only one considered the test was not easy to perform with the support of the quick guide.

The authors concluded that the performance of the VIKIA Malaria AgPf/Pan rapid test performed by traditional end-users in field conditions is similar to those obtained by a trained scientific team, and that VIKIA Malaria AgPf/Pan can be considered as a point-of-care test. In addition, the protocol designed for this study, using well-characterized and calibrated blood samples could be used systematically in parallel to conventional evaluation studies to determine the performance of malaria RDTs in field conditions. The study was published on March 14, 2015, in the Malaria Journal.

Related Links:

Institut Pasteur du Cambodge 
IMACCESS/bioMérieux 



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
New
PlGF Test
Quidel Triage PlGF Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.